Pulmonary Vasodilation by Sildenafil in Acute Intermediate-High Risk Pulmonary Embolism – A Randomized Explorative Trial

Asger Andersen (✉ asgerandersen@gmail.com)
Aarhus Universitetshospital  https://orcid.org/0000-0002-9102-3130

Farhad Waziri
Aarhus Universitetshospital, Dep. of Cardiology

Jacob Gammelgaard Schultz
Aarhus University Hospital, Dep. of Cardiology

Sarah Holmboe
Aarhus University Hospital, Dep. of Cardiology

Søren Warberg Becker
Region Hospital of Silkeborg, Diagnostic Centre

Tage Jensen
Region Hospital Randers, Dep. of Internal Medicine

Hanne Maare Søndergaard
Region Hospital Viborg, Dep. of Cardiology

Karen Kaae Dodt
Region Hospital Horsens, Dep. of Internal Medicine

Ole May
Region Hospital Herning, Dep. of Cardiology

Ulrik Markus Mortensen
Aarhus University Hospital, Dep. of Cardiology

Won Yong Kim
Aarhus University hospital, Dep. of Cardiology

Søren Mellemkjær
Aarhus University Hospital, Dep. of Cardiology

Jens Erik Nielsen-Kudsk
Aarhus University Hospital, Dep. of Cardiology

Research article

Keywords: Pulmonary Embolism, Sildenafil, PDE5 inhibition, Pulmonary vasodilation
Abstract

Background: To investigate if acute pulmonary vasodilation by sildenafil improves right ventricular function in patients with acute intermediate-high risk pulmonary embolism (PE).

Methods: Single center, explorative trial. Patients with PE were randomized to a single oral dose of sildenafil 50mg (n=10) or placebo (n=10) as add-on to conventional therapy. The time from hospital admission to study inclusion was 2.3 ± 0.7 days. Right ventricular function was evaluated immediately before and shortly after (0.5-1.5h) randomization by right heart catheterization (RHC), trans-thoracic echocardiography (TTE), and cardiac magnetic resonance (CMR). The primary efficacy endpoint was cardiac index measured by CMR.

Results: Patients had acute intermediate-high risk PE verified by computed tomography pulmonary angiography, systolic blood pressure of 135 ± 18 (mean ± SD) mmHg, increased right ventricular/left ventricular ratio 1.1 ± 0.09 and increased troponin T 167 ± 144 ng/L. Sildenafil treatment did not improve cardiac index compared to baseline (0.02 ± 0.36 l/min/m², p=0.89) and neither did placebo (0.00 ± 0.34 l/min/m², p=0.97).

Conclusion: A single oral dose of sildenafil 50 mg did not improve cardiac index but lowered systemic blood pressure in patients with acute intermediate-high risk PE. The time from PE to intervention, a small patient sample size and low pulmonary vascular resistance are limitations of this study that should be considered when interpreting the results.

1 Background

Acute pulmonary embolism (PE) is a potentially fatal disease with a broad spectrum of clinical presentations. It may vary from subtle changes in functional capacity to hemodynamic collapse and death depending on the thromboembolic mass obstructing the pulmonary circulation and the associated vasoactive response of the pulmonary arteries. In patients with high risk PE, mortality ranges from 25-52% and in patients with intermediate-high risk PE, mortality ranges from 8-15%.(1,2) The true incidence of PE is difficult to assess, but with an estimated incidence of 6-20/10000/year in Europe and the United States(3-5) it is a common acute cardiovascular disease.

The treatment of choice is based on the severity of hemodynamic changes and the degree of right ventricular dysfunction. Cornerstones in the treatment of PE are anticoagulation therapy in most patients and thrombolysis in hemodynamic unstable patients. Other treatment options are surgical or catheter based embolectomy or fragmentation of the thrombus mass.(6-8) Despite modern management, PE is still a fatal disease with a high risk of death in patients with intermediate or high-risk PE. (6)

The ultimate cause of death in PE is right heart failure due to the acute increase in afterload.(7) This is not only due to mechanical obstruction of the proximal pulmonary arteries but also caused by active
pulmonary vasoconstriction mediated by hypoxemia, a neurogenic reflex and the release of vasoconstrictors from activated lung cells, endothelial cells, platelets, and leukocytes. (8-11)

As current therapies mainly focus on removing the mechanical obstruction there may be a potential for pulmonary vasodilators as add-on to current treatment strategies. Inhaled nitric oxide (NO) has shown promising results in case reports(12) and the treatment was found to be safe in a phase 1 clinical trial. (13) A recent randomized clinical trial failed at meeting its primary endpoint of normalization of echocardiogram and troponins, but there was improvement in RV function in PE patients treated with NO. (14) Administration of NO is by inhalation trough a nasal cannula or via mechanical ventilation and long-term treatment is not feasible. Pharmacological stimulation of the NO vasodilatory pathway by the oral route may be an attractive alternative to NO therapy.

NO exerts its vasodilator action by up-regulating intracellular cyclic guanosine mono phosphate (cGMP) in the smooth muscle cells of the pulmonary vasculature. cGMP is converted to the inactive 5’GMP by phosphodiesterase type 5 (PDE5). Hence, another strategy for pulmonary vasodilation is inhibition of the breakdown of cGMP by sildenafil, a specific PDE5 inhibitor widely used in the treatment of pulmonary arterial hypertension. Supporting the biologic rationale for the use of sildenafil in the treatment of PE is a series of pre-clinical studies and few case reports of its efficacy. (15-1) Furthermore, the ease of use and the low cost makes sildenafil an attractive therapy as add-on to conventional therapy. The aim of this trial was to test the acute effects on right ventricular function of pulmonary vasodilation by sildenafil administered as a single oral dose 50 mg as add-on to conventional therapy in patients with acute intermediate-high risk PE.

### 2 Methods

#### 2.1 Patients

Patients with acute pulmonary embolism confirmed by contrast enhanced computed tomography (CT) were eligible for inclusion if they had symptom duration of less than 14 days, were older than 18 years and had a right ventricular/left ventricular ratio (RV/LV) >1 measured by trans-thoracic echocardiography (TTE, 1 cm above the atrio-ventricular valves in the four-chamber view at end-diastole). Patients were excluded if they were pregnant, had cardiac arrest that required cardiopulmonary resuscitation, a life expectancy <120 days, systolic blood pressure <90 mmHg, metal implants, obesity or claustrophobia that excluded the patient from cardiac magnetic resonance (CMR), altered mental status making the patient unable to provide informed consent, recent use of drugs with influence on the NO-cGMP pathway, known or suspected chronic thromboembolic pulmonary hypertension, inability to perform study protocol < 72 hours after conventional PE treatment was instituted or active bleeding after thrombolysis. Patients were screened for inclusion at hospitals in the Central Region of Denmark.

#### 2.2 Protocol
The study was designed as a single centre, prospective, randomized, placebo-controlled, double-blind, explorative trial. If eligible for inclusion, the patient was transferred to Aarhus University Hospital to complete the study protocol. To characterize the patients, RV/LV ratio was calculated from the CT scan and by TTE performed at the local institution on the day of diagnosis. Cardiac biomarkers (troponin T/I, N-terminal pro-brain natriuretic peptide (NT-proBNP)), height, weight, respiratory frequency, peripheral saturation, and pulse were measured at the local institution on the day of screening and by the study site on the day of inclusion. A detailed medical history was collected including duration of symptoms, known active cancer, recent surgery/trauma, chronic obstructive pulmonary disease, diabetes mellitus, oestrogen therapy, and/or immobilisation.

During the study protocol (figure 1), right ventricular function was evaluated on the same day before and shortly after (0.5-1.5h) randomization to sildenafil 50 (n=10) mg or placebo (n=10) with CMR, TTE and RHC. Primary efficacy endpoint was cardiac index (CI) evaluated by CMR. Blood pressure was evaluated at 30, 45, 120 and 180 min after randomization as a safety measure. Other hemodynamic parameters were analysed as exploratory endpoints. Exploratory endpoints evaluated by TTE were RV/LV ratio, fractional area change (FAC), tricuspid annular plane excursion (TAPSE), pulmonary artery acceleration time (PAAT) and tricuspid regurgitation gradient (TR). Exploratory endpoints evaluated by CMR were heart rate (HR), RV stroke volume (SV), RV end-diastolic volume (EDV), RV end-systolic volume (ESV), right ventricular ejection fraction (EF), mean peak longitudinal strain (MPLS). Exploratory endpoints evaluated by right heart catheterization were mean pulmonary capillary wedge pressure (mPCWP), diastolic-, systolic- and mean pulmonary artery pressure (dPAP, sPAP, mPAP), mixed venous oxygen saturation (SvO$_2$) and pulmonary vascular resistance (PVR). Detailed protocols for TTE, CMR and RHC are available in the supplemental material. Study drugs (sildenafil or placebo) were prepared in quickly absorbable gelatinous caps by the institutional pharmacy to blind both patients and the physicians to treatment. Patients were randomized in blocks of 10 with sequentially randomly numbered containers. The randomization key was disclosed by the institutional pharmacy after data analysis was complete. All analyses were performed with the observer blinded to treatment. The study was performed and data collected at Aarhus University Hospital, Denmark. The study adheres to CONSORT guidelines.

### 2.3 Statistics

Sample size was calculated to be 10 patients in each treatment group. The calculation was based on the assumptions of a power of 0.9 and $\alpha$ of 0.05 to detect a paired difference of 29 mL/kg/min change in cardiac index with standard deviation of the difference to be 25 mL. Normality testing was performed with the Shapiro-Wilk test. Within-group comparison of continuous data was performed using the two-sided paired t-test. Between-group continuous data and baseline patient characteristics were compared using the two-sided unpaired Students t-test as an explorative analysis. Two-way ANOVA testing was performed to test differences in systemic blood pressure between groups. If data was not normally distributed, non-parametric tests were used (Wilcoxon matched pairs signed-rank or rank sum test).
accordingly. All data are presented as mean ± standard deviation (SD). P £ 0.05 was considered statistically significant.

3 Results

3.1 Patients

We enrolled 21 patients from the 1st of March 2015 through 10th of September 2017 and randomly assigned 20 patients to a single 50 mg dose of sildenafil (n=10) or placebo (n=10). All patients randomized to treatment had acute PE verified by CT pulmonary angiography, increased RV/LV ratio measured on CT and TTE and increased cardiac biomarkers measured by troponin T/I and/or NT-proBNP. More patients had previous deep venous thromboses in the placebo group. None of the patients were treated with thrombolysis. Other baseline characteristics were similar in both groups (Table 1). Time from hospital admission and initiation of conventional therapy to study inclusion were 2.3 ± 0.7 days. Mean CI for all patients included was 2.3 ± 0.6 l/min/m². CMR was performed in all patients. Inclusion rate was low initially as several patients wanted to avoid right heart catheterization (RHC). To improve inclusion rate, RHC was made optional 4 months after initiation of the study. RHC was performed in 16 patients (sildenafil n=8 and placebo n=8). TTE were performed in all patients, but the results from 2 patients were excluded before unblinding due to poor image quality (placebo n=2). One patient did not have RV/LV >1 on TTE on the day of inclusion and was excluded as screening failure before randomization.

3.2 Primary and explorative endpoints for right ventricular function

Primary and explorative endpoints are summarized in figure 2A and table 1. Time from administration of study drug to right ventricular evaluation were 32 ± 5 min for RHC, 74 ± 17 min for CMR, and 84 ± 40 min for TTE. Sildenafil did not improve cardiac index (primary endpoint) measured by CMR (Placebo baseline vs. follow up 2.28 ± 0.40 vs. 2.29 ± 0.54, p=0.97; sildenafil baseline vs. follow-up 2.37 ± 0.70 vs. 2.38 ± 0.61, p=0.89). Exploratory endpoints measured by CMR revealed that sildenafil significantly reduced end-diastolic and end-systolic RV volume. mPCWP increased with placebo but was unaltered by sildenafil. PAAT was shortened after placebo treatment but was unaltered by sildenafil. Other exploratory endpoints were unaltered both by sildenafil and placebo.

3.3 Safety

None of the patients reported adverse events. Blood pressure was lower in sildenafil treated patients compared to placebo (figure 2B). The maximal drop in blood pressure was observed 120 min after administration of study drug (sildenafil: -19 ± 10, placebo: 0 ± 9 mmHg, p=0.0007) to a MAP of 91 ± 14 mmHg in the sildenafil and 104 ± 10 in the placebo treated patients. The largest drop in systemic blood pressure in a single patient was from 146/95 to 94/64 mmHg observed 180 min after sildenafil treatment.
4 Discussion

Pulmonary vasodilation by sildenafil have shown benefit in experimental models of acute pulmonary embolism and in case reports. This is the first randomized controlled trial to test sildenafil in patients with acute intermediate-high risk pulmonary embolism.

In a previous trial, epoprostenol failed to show benefit on the RV in patients with acute PE. However, patients in that trial had only slight RV dysfunction making it difficult to demonstrate a hemodynamic benefit of pulmonary vasodilatation. In the current trial, all patients had an increased RV/LV ratio and an increase in cardiac biomarkers. With a blood pressure >90 mmHg the patients are characterized as intermediate-high risk PE according to current guidelines from the European Society of Cardiology. Cardiac index measured by CMR was lower than healthy individuals and similar to patients with congestive heart failure in NYHA class III-IV. Also, mPAP was increased compared to healthy individuals. Therefore, it is unlikely that patient selection with regards to the severity of the disease can explain the overall neutral result of this trial.

We used several independent methods to evaluate RV function. Previous and ongoing studies on a similar topic have used RV/LV ratio measured by echo as a primary endpoint. By the use of a more elaborate RV evaluation in this study we could potentially measure subtle hemodynamic changes even with a low number of patients. In the exploratory endpoints, we did find a reduction in EDV and ESV. With an unaltered PVR, these changes could simply be secondary to the observed lower systemic blood pressure which emphasizes the accuracy of the hemodynamic evaluation.

We chose to test the acute effects of pulmonary vasodilation after administration of a single dose of sildenafil 50 mg as this design has previously proven to be effective in PAH patients and in preclinical studies of PE. The observation of a lowered MAP at several independent timepoints after administration similar to previous observations confirm that sildenafil was administered in an effective dose and that the effect was evaluated at relevant timepoints after administration.

The magnitude of MAP lowering together with the observation that none of the patients reported adverse events suggest that sildenafil was safe in our patients. It should however be emphasized that data is limited and we cannot conclude that sildenafil is generally safe in acute PE based on our data alone.

5 Limitations

There are some limitations to our study. One is the delay of 2.3 days from initiation of conventional therapy to study inclusion. It has been suggested that vasoconstriction is more pronounced in the early phase after PE and not so much in the later phase. Hence, the potential effect of pulmonary vasodilation in acute PE would be blunted at study inclusion more than 2.3 days after hospital admission. There are limited clinical data supporting this speculation but as experimental data suggest, the efficacy of pulmonary vasodilation is attenuated during the first 12 hours in the initial phase after PE which could explain the discrepancy between the positive experimental studies that initiate
pulmonary vasodilation shortly after PE and the few, but all neutral clinical studies where onset of
treatment is delayed.

We observed a higher than expected left atrial pressure yielding a near-normal PVR. This finding could
explain the overall neutral result of this trial, as sildenafil is most effective in treating pre-capillary
pulmonary vasoconstriction. (26) It should, however be taken into consideration that the patients did
have a high thrombus burden increasing the risk of over-wedging and a possible false high wedged
pressure.

Another limitation is the low number of patients included in the trial. Being an exploratory study, we
choose an elaborate hemodynamic evaluation of the patients to identify possible hemodynamic
changes. Post-hoc power calculation revealed that 3924 patients should be included to show a
significant difference with a power of 0.8 and α of 0.05 to detect a paired difference of the observed 17
mL/m²/min change in cardiac index using the observed standard deviation of 380 mL/m²/min. Looking
at Figure 2 however, there is one sildenafil treated patient with a CI of 3.8 L/m²/min at baseline and as
discussed previously there would be rationale behind excluding patients with a high cardiac output in
future trials. If this was done in this trial with a cut-off of CI < 3 L/m²/min, a non-significant improvement
of 112 mL/m²/min was observed (p=0.2). Although speculative, this observation could be of use in future
trials. A post hoc power calculation for the more widely used RV/LV ratio as primary endpoint using the
observed 0.04 change in RV/LV ratio with SD of 0.16 reveals that 128 patients should be included to
show an effect in the treatment arm with a power of 0.8 and α of 0.05 suggesting that RV/LV ratio may
be a more robust primary endpoint in future trials. The calculations above discuss statistical effect.
Whether or not these small improvements in hemodynamics would translate into a clinical effect is
unknown.

The limitations in this trial should be taken into consideration in the interpretation of the data. There is
substantial experimental evidence in a wide range of PE models that pulmonary vasodilation improve
hemodynamics in acute PE(10) but still, there are only a very limited number of small clinical trials.
Therefore, it would still be relevant to explore the clinical potential of pulmonary vasodilation in acute PE.
Patient selection with regards to high RV/LV ratio, high PVR, low CI and timing will probably be key to
success in future trials.

6 Conclusion

In conclusion we found that a single dose of sildenafil 50 mg lowered systemic blood pressure but did
not improve cardiac index in patients with acute intermediate-high risk pulmonary embolism. The time
from PE to intervention, a small patient sample size and low pulmonary vascular resistance are
limitations of this study that should be considered when interpreting the results.

7 Abbreviations
8 Declarations

8.1 Ethics Approval and Consent to Participate

The study protocol was approved by the Danish Ethics Committee in the Central Region of Denmark (File# 44099) and study data management by the Danish Data Protection Agency in the Central Region of Denmark (File# 1-16-02-574-14). All patients gave informed written consent before inclusion. The study was retrospectively registered February 2\textsuperscript{nd} 2020 at www.clinicaltrials.gov (NCT04283240).

8.2 Consent for Publication

Not applicable

8.3 Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request. Protocol and detailed methods and materials are available in the supplementary.

8.4 Competing Interests

AA have received travel grants and lecturing fees from MSD, Medtronic, Abbot, Astra Zenica, Boehringer Ingelheim. JS has received lecturing fees from MSD. SB have received travel grants from Pfizer/BMS and Boehringer Ingelheim. HMS have received travel grants and lecturing fees from Astra Zeneca. SM, WYK, OM, SH, KKD, FW, JENK, TJ, UMM report no conflicts of interest.

8.5 Funding

The study was investigator initiated and driven. The study was funded by the Novo Nordisk Foundation (NNF16OC0023244). NNF had no role in designing the study, data collection, data analysis, data interpretation or writing of the report.

8.6 Author contribution
Study design (AA, JENK, SM). Patient inclusion and data collection (AA, JS, SM, SB, WYK, OM, SH, KKD, FW, JENK, TJ, UMM, JENK). Data analysis and interpretation (AA, WYK, JS, SH, JENK, SM). Writing and critical review of the paper ( AA, JS, SM, SB, WYK, OM, SH, KKD, FW, JENK, TJ, UMM, JENK). All authors read and approved the final manuscript.

8.7 Acknowledgements

Dorte Frydendahl is complimented for her help during the days of study inclusion. Mads Jønsson Andersen, Henrik Wiggers, Brian Bridal Løgstrup and Hans Eiskjær are thanked for their help with the RHCs.

9 References

1. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation. 2006 Jan 31;113(4):577-82.
2. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997 Nov 1;30(5):1165–71.
3. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000 May;83(5):657–60.
4. Nordström M, Lindblad B. Autopsy-verified venous thromboembolism within a defined urban population—the city of Malmö, Sweden. APMIS. 1998 Mar;106(3):378–84.
5. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975 Jan;17(4):259–70.
6. Nakamura M, Miyata T, Ozeki Y, Takayama M, Komori K, Yamada N, et al. Current Venous Thromboembolism Management and Outcomes in Japan. Circ J. 2014;78(3):708-17.
7. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol. 1971 Sep;28(3):288–94.
8. Lualdi JC, Goldhaber SZ. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J. 1995 Dec;130(6):1276–82.
9. Barnes PJ, Liu SF. Regulation of pulmonary vascular tone. Pharmacol Rev. 1995 Mar;47(1):87-131.
10. Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res. 2000 Oct;48(1):23–33.
11. Lyhne MD, Kline JA, Nielsen-Kudsk JE, Andersen A. Pulmonary vasodilation in acute pulmonary embolism - a systematic review. Pulm Circ. 2020 Mar;10(1):1-16
12. Summerfield DT, Desai H, Levitov A, Grooms DA, Marik PE. Inhaled nitric oxide as salvage therapy in massive pulmonary embolism: a case series. Respir Care. 2012 Mar;57(3):444–8.

13. Kline JA, Hernandez J, Garrett JS, Jones AE. Pilot study of a protocol to administer inhaled nitric oxide to treat severe acute submassive pulmonary embolism. Emerg Med J. 2013 Dec;25(6):515-6.

14. Kline JA, Puskarich MA, Jones AE, Mastouri RA, Hall CL, Perkins A, et al. Inhaled nitric oxide to treat intermediate risk pulmonary embolism: A multicenter randomized controlled trial. Nitric Oxide. 2019 Mar;84:60-68.

15. Dias-Junior CA, Vieira TF, Moreno H, Evora PR, Tanus-Santos JE. Sildenafil selectively inhibits acute pulmonary embolism-induced pulmonary hypertension. Pulm Pharmacol Ther. 2005;18(3):181–6.

16. Bonatti HJR, Harris T, Bauer T, Enfield K, Sabri S, Sawyer RG, et al. Transfemoral catheter thrombolysis and use of sildenafil in acute massive pulmonary embolism. J Cardiothorac Vasc Anesth. 2010 Dec;24(6):980–4.

17. Ganière V, Feihl F, Tagan D. Dramatic beneficial effects of sildenafil in recurrent massive pulmonary embolism. Intensive Care Med. 2006 Mar;32(3):452–4.

18. Schultz J, Andersen A, Gade IL, Kjaergaard B, Nielsen-Kudsk JE. Riociguat, sildenafil and inhaled nitric oxide reduces pulmonary vascular resistance and improves right ventricular function in a porcine model of acute pulmonary embolism. Eur Heart J Acute Cardiovasc Care. 2020 Jun;9(4):293-301.

19. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2019 Aug 31;39:4208.

20. Carlsson M, Andersson R, Bloch KM, Steding-Ehrenborg K, Mosén H, Stahlberg F, et al. Cardiac output and cardiac index measured with cardiovascular magnetic resonance in healthy subjects, elite athletes and patients with congestive heart failure. J Cardiovasc Magn Reson. 2012 Jul 28;14(1):51.

21. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Resp J. 2009 Oct;34(4):888–94.

22. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaš B, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004 Oct 6;44(7):1488–96.

23. Kooter AJ, Ijzerman RG, Kamp O, Boonstra AB, Smulders YM. No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial. BMC Pulm Med. 2010;10:18.

24. Utsunomiya T, Krausz MM, Valeri CR, Shepro D, Hechtman HB. Treatment of pulmonary embolism with prostacyclin. Surgery. Elsevier; 1980 Jul 1;88(1):25–30.

25. Kramer A, Mortensen CS, Schultz JG, Lyhne MD, Andersen A, Nielsen-Kudsk JE. Inhaled nitric oxide has pulmonary vasodilator efficacy both in the immediate and prolonged phase of acute pulmonary embolism. Eur Heart J Acute Cardiovasc Care. 2020 doi:10.1177/2048872620918713.
Tables

Table 1: Baseline patient characteristics.
|                          | Placebo (SD) | Sildenafil (SD) | p-value |
|--------------------------|--------------|----------------|---------|
|                          | n=10         | n=10           |         |
| Age (years)              | 72 (9)       | 63 (9)         | 0.09    |
| Female (%)               | 50           | 30             | 0.51    |
| Height (cm)              | 170 (10)     | 171 (7)        | 0.87    |
| Weight (kg)              | 87 (13)      | 86 (10)        | 0.83    |
| BMI (kg/m2)              | 30 (3)       | 30 (4)         | 0.77    |
| Known Active Cancer (%)  | 0            | 0              | 1.00    |
| Immobilisation (%)       | 10           | 20             | 0.59    |
| Recent surgery/trauma (%)| 10           | 20             | 0.59    |
| Previous VTE (%)         | 50           | 10             | 0.04    |
| COPD (%)                 | 0            | 20             | 0.17    |
| DM (%)                   | 30           | 10             | 0.17    |
| Smoking (%)              | 10           | 10             | 1.00    |
| Estrogen (%)             | 10           | 10             | 1.00    |
| Duration of symptoms (d) | 3.0 (1.3)    | 2.7 (1.3)      | 0.66    |
| UFH/LMH/VKA/NOAK (n)     | 2/7/0/1      | 0/9/0/1        | na      |
| Oxygen therapy (l)       | 1.8 (1.4)    | 1.9 (1.9)      | 0.85    |
| TnT (ng/l)               | 198 (131)    | 136 (150)      | 0.66    |
| NT proBNP (ng/l)         | 6573 (8624)  | 1201 (113)     | 0.08    |
| RF (/min)                | 18 (3)       | 19 (3)         | 0.19    |
| Periferal saturation (%) | 96 (2)       | 95 (2)         | 0.13    |
| Pulse (BPM)              | 70 (9)       | 85 (12)        | 0.02    |
| BPs (mmHg)               | 134 (10)     | 137 (24)       | 0.55    |
| BPd (mmHg)               | 81 (9)       | 88 (12)        | 0.25    |
| RV diameter* (cm)        | 5.4 (0.5)    | 5.2 (0.8)      | 0.70    |
| LV diameter* (cm)        | 3.7 (0.5)    | 3.2 (0.5)      | 0.06    |
| RV/LV*                   | 1.5 (0.3)    | 1.7 (0.5)      | 0.23    |
BMI body mass index. VTE venous thrombus embolism. COPD chronic obstructive pulmonary disease. DM diabetes mellitus. UFH unfractioned heparin. LMH low molecular weight heparin. VKA vitamin-K antagonist. NOAK non-vitamin-K oral anti-coagulation. TnT troponin-T. NT-proBNP N-terminal pro brain natriuretic peptide. RF respiratory frequency. BPs systolic blood pressure. BPd diastolic blood pressure. RV right ventricle. LV left ventricle. RV/LV right ventricular/left ventricular diameter ratio. *measured by computed tomography at the day of screening for inclusion. Data is reported as mean ± SD

Table 2: exploratory endpoints.
|                              | Placebo |         |         | Sildenafil |         |         |
|------------------------------|---------|---------|---------|------------|---------|---------|
|                              | Baseline| Follow Up| p-value | Baseline  | Follow up| p-value |
| **HR (BPM)**                 | 69 (9)  | 68 (7)  | 0.49    | 84 (12)   | 85 (12) | 0.58    |
| **CMR derived parameters**   |         |         |         |            |         |         |
| RV SV (mL)                   | 68 (19) | 68 (18) | 0.96    | 57 (19)   | 58 (22) | 0.84    |
| CO (l/min)                   | 4.53 (0.94) | 4.54 (1.14) | 0.97 | 4.71 (1.44) | 4.76 (1.34) | 0.89 |
| RV EDV (mL)                  | 222 (19) | 222 (12) | 1.00    | 193 (73)  | 184 (76) | 0.05    |
| RV ESV (mL)                  | 152 (18) | 153 (15) | 0.77    | 135 (62)  | 125 (62) | 0.04    |
| RV EF (%)                    | 32 (8)  | 31 (8)  | 0.50    | 31 (8)    | 34 (9)  | 0.14    |
| MPLS (%)                     | -12.3 (3.4) | -13.1 (3.4) | 0.17 | -12.9 (4.1) | -13.1 (4.0) | 0.89 |
| **RHC derived parameters**   |         |         |         |            |         |         |
| mPCWP (mmHg)                 | 11.1 (4.5) | 12.4 (4.4) | **0.02** | 17.0 (4.9) | 15.0 (3.7) | 0.14 |
| PAPd (mmHg)                  | 15.7 (3.2) | 17.6 (2.6) | 0.31    | 17.1 (3.1) | 17.0 (6.7) | 0.96    |
| PAPs (mmHg)                  | 47.0 (6.6) | 47.4 (4.8) | 0.92    | 47.0 (7.7) | 42.9 (5.3) | 0.21    |
| mPAP (mmHg)                  | 27.0 (2.9) | 27.6 (2.4) | 0.66    | 27.3 (3.7) | 25.3 (3.4) | 0.30    |
| PVR (wood)                   | 3.5 (1.0)  | 3.5 (1.4)  | 0.86    | 2.3 (1.0)  | 2.0 (1)   | 0.43    |
| SVO₂ (%)                     | 62.6 (6.7) | 64.4 (8.5) | 0.29    | 65.9 (8.5) | 65.2 (7.3) | 0.67    |
| **TTE derived parameters**   |         |         |         |            |         |         |
| RV/LV                        | 1.10 (0.05) | 1.12 (0.19) | 0.39    | 1.12 (0.11) | 1.08 (0.21) | 0.47 |
| RV FAC (%)                   | 0.30 (0.14) | 0.30 (0.11) | 0.98    | 0.34 (0.15) | 0.37 (0.14) | 0.28 |
| TAPSE (cm)                   | 1.79 (0.44) | 1.78 (0.56) | 0.86    | 1.69 (0.36) | 1.79 (0.44) | 0.33 |
### Table

| PAAT (ms) | 64 (12) | 54 (12) | 0.02 | 61 (8) | 64 (13) | 0.40 |
|-----------|---------|---------|-------|--------|---------|------|
| TI (mmHg) | 36 (8)  | 36 (10) | 0.81  | 33 (8) | 31 (3)  | 0.52 |

**HR** heart rate. **CMR** cardiac magnetic resonance imaging. **RV SV** right ventricular stroke volume. **CO** cardiac output. **RV EDV** right ventricular end diastolic volume. **RV ESV** right ventricular end systolic volume. **RV EF** right ventricular ejection fraction. **MPLS** mean peak longitudinal strain. **mPCWP** mean pulmonary capillary wedge pressure. **PAPd** diastolic pulmonary artery pressure. **PAPs** systolic pulmonary artery pressure. **mPAP** mean pulmonary artery pressure. **PVR** pulmonary vascular resistance. **SVO₂** mixed venous oxygen saturation. **RV/LV** right ventricular/left ventricular diameter ratio. **RV FAC** right ventricular fractional area change. **TAPSE** tricuspid annular plane systolic excursion. **PAAT** pulmonary artery acceleration time. **TI** tricuspid regurgitation gradient. Data is reported as mean ± SD

### Figures

**Baseline hemodynamics**

**Follow up hemodynamics**

![Figure 1](image)

**Figure 1**

Study design. CMR cardiac magnetic resonance imaging. TTE trans-thoracic echocardiography. RCH right heart catheterization. R randomisation sildenafil 50 mg or placebo. * measurement of blood pressure.
Figure 2

A) Primary efficacy endpoint. CI cardiac index measured by cardiac magnetic resonance imaging B) Safety endpoint. MAP mean arterial blood pressure. *** p<0.001

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementary.docx